"Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine" ed. by Ana Colette Mauricio

This volume is dedicated to Umbilical cord blood (UCB) and, more recently, umbilical cord tissue (UCT) have been stored cryopreserved in private and public cord blood and tissue banks worldwide, since the umbilical cord blood was used for the first time in a child with Fanconi anemia with his HLA-identical sibling, following strict guidelines that imply high-quality standards and total rastreability of these units.

The hematopoietic stem cells (HSCs) are clinically used in hematopoietic treatments for blood disorders and hemato-oncological diseases. Also, the mesenchymal stem cells (MSCs) isolated from the UCT and UCB, nowadays, can be used as coadjuvants of hematopoietic transplants. In the near future, these stem cells will have a crucial role in regenerative medicine. For this reason, these cells have been tested in several clinical trials and compassive treatments in children and adults, concerning a wide range of pathologies and diseases, for instance, for the treatment of cerebral paralysis. Considering the worldwide availability of UCB and UCT units and the absence of ethical concerns will probably become the best sources for cell-based therapies for hematological and nonhematological pathologies.
The UCB will also have a crucial role in neonatology-predictive analysis in the near future.

Contents
Preface
1 Cord Blood Stem Cell Processing, Banking and Thawing
2 Reference Intervals of Platelets, Lymphocytes and Cardiac Biomarkers in Umbilical Cord Blood
3 Future Perspectives in HLA Typing Technologies
4 Hypercortisolaemia and Hyperinsulinaemia Interaction and their Impact upon Insulin Resistance/Sensitivity Markers at Birth
5 Umbilical Cord Blood Cells for Perinatal Brain Injury: The Right Cells at the Right Time?
6 Umbilical Cord Blood Hematopoietic Stem and Progenitor Cell Expansion for Therapeutic Use
7 Umbilical Cord Blood-Derived Therapies as a Treatment for Graft-Versus-Host Disease
8 Optimization of Unrelated Donor Cord Blood Transplantation for Thalassemia: Implications for Other Non‐Malignant Indications such as HIV Infection or Autoimmune Diseases
9 Myoblast Differentiation of Umbilical Cord Blood Derived Stem Cells on Biocompatible Composites Scaffold Meshes